Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates.
The phenomenon of cross-resistance to antiretroviral agents used to treat human immunodeficiency virus type 1 infection is well known but so far has been only qualitatively described. Here, we quantitate the degree of cross-resistance among all commonly prescribed antiretroviral agents in almost 5,000 clinically derived recombinant isolates collected in the United States since January 2000.
Harrigan
P Richard
PR
Virco UK Ltd., Cambridge, United Kingdom.
Larder
Brendan A
BA
D019380:Anti-HIV Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D010641:Phenotype; D012044:Regression Analysis; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D014481:United States
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase